Ventyx biosciences announces positive preclinical data for cns-penetrant nlrp3 inhibitor vtx3232 demonstrating reversal of obesity and improvements in cardiometabolic and inflammatory markers

Vtx3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (dio) mice

VTYX Ratings Summary

VTYX Quant Ranking